ClinicalTrials.Veeva

Menu
A

Alliance for Multispecialty Research, LLC | AMR Mobile, AL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Cytisinicline
Vicadrostat
Orforglipron
Reloxaliase
Allopurinol
BI 690517
LY3502970
BW-00112
Retatrutide
RGT001-075

Parent organization

This site is a part of Alliance for Multispecialty Research, LLC

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 20 total trials

A Study in Patients with Mixed Dyslipidemia

A Phase 2 in Patients With Mixed Dyslipidemia

Enrolling
Mixed Dyslipidemia
Drug: BW-00112

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF...

Enrolling
Respiratory Syncytial Virus (RSV)
Biological: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE
Biological: HZ/su VACCINE

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo
Locations recently updated

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People ca...

Begins enrollment in 1 month
Heart Failure
Drug: Placebo matching vicadrostat
Drug: Empagliflozin

The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunoge...

Active, not recruiting
Chikungunya Virus Infection
Biological: Placebo booster
Biological: CHIKV VLP vaccine booster

Safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the U...

Active, not recruiting
Vaping Cessation
Smoking Cessation
Drug: Cytisinicline

This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss...

Active, not recruiting
Obesity or Overweight
Drug: Placebo Comparator
Drug: RGT001-075

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Drug: Retatrutide
Drug: Placebo

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the effi...

Enrolling
Hyperuricemia
Tophi
Drug: Allopurinol
Drug: Tigulixostat

Trial sponsors

BioNTech logo
Pfizer logo
Lilly logo
Achieve Life Sciences logo
A
Bavarian Nordic logo
Boehringer Ingelheim logo
LG Chem logo
Organon logo
R

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems